Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000351450

Medchemexpress LLC TAN-452 | 892039-23-5 | 99.4% | 486.56 | 1 ML
SDP

Catalog No. 5000351450
Encompass_Preferred

TAN-452 is an orally active, selective peripherally acting δ-opioid receptor (DOR) antagonist, derived from Naltrindole. It demonstrates low brain penetrability and is primarily used for research purposes. This compound acts as a selective antagonist for the δ-opioid receptor with a Ki of 0.47 nM and a Kb of 0.21 nM, and also exhibits antagonistic activity for the μ-opioid receptor (MOR) and κ-opioid receptor (KOR).

  • Orally active and selective peripherally acting δ-opioid receptor antagonist.
  • Low brain penetrability.
  • Attenuates morphine-induced side effects without impacting pain control.
  • Suppresses morphine-induced emesis in ferrets.
  • Inhibits morphine-induced small intestinal transit in a dose-dependent manner.
  • Significantly suppresses morphine-induced antinociception when administered subcutaneously.
  • Investigated for the treatment of opioid-induced bowel syndromes.

Catalog No. 50-003-51450 Supplier Medchemexpress LLC Supplier No. HY13620810MM/1ML
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

TAN-452 is an orally active, selective peripherally acting δ-opioid receptor (DOR) antagonist, derived from Naltrindole. It demonstrates low brain penetrability and is primarily used for research purposes. This compound acts as a selective antagonist for the δ-opioid receptor with a Ki of 0.47 nM and a Kb of 0.21 nM, and also exhibits antagonistic activity for the μ-opioid receptor (MOR) and κ-opioid receptor (KOR).

  • Orally active and selective peripherally acting δ-opioid receptor antagonist.
  • Low brain penetrability.
  • Attenuates morphine-induced side effects without impacting pain control.
  • Suppresses morphine-induced emesis in ferrets.
  • Inhibits morphine-induced small intestinal transit in a dose-dependent manner.
  • Significantly suppresses morphine-induced antinociception when administered subcutaneously.
  • Investigated for the treatment of opioid-induced bowel syndromes.

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.